Dalfopristin Production Cost Reports

The report provides a detailed analysis essential for establishing a dalfopristin production plant. It encompasses all critical aspects necessary for dalfopristin production, including the cost of dalfopristin production, dalfopristin plant cost, dalfopristin production costs, and the overall dalfopristin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a dalfopristin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Dalfopristin is a streptogramin antibiotic that finds specialised applications in the medical and pharmaceutical industries. It is primarily utilised as a drug in combination with quinupristin to treat serious bacterial infections caused by Gram-positive bacteria, including strains resistant to other antibiotics (Enterococcus faecium bacteria and methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes).

It is primarily used to treat serious skin and skin structure infections caused by staphylococci or streptococci that resist other drugs. It is also used in the treatment of life-threatening bloodstream infections from vancomycin-resistant Enterococcus faecium. Moreover, it also helps manage complicated intra-abdominal infections and nosocomial pneumonia linked to resistant gram-positive bacteria.

The market for dalfopristin is driven by its application as a semi-synthetic streptogramin antibiotic to treat serious bacterial infections, which boosts its demand in the medical sector. Its utilisation as a drug for the treatment of vancomycin-resistant Enterococcus faecium (VREF) bacteremia and complicated skin infections significantly promotes its demand in the pharmaceutical industry. Its application in combination therapy with quinupristin to manage infections such as complicated skin infections and bloodstream infections largely supports its demand in the medical and pharmaceutical industries.

Its demand in research and development for creating new antibacterial drugs and improving existing therapies also adds to its market growth. In addition, the rising concern over antimicrobial resistance increases the need for effective last-line antibiotics, which further boosts demand. Moreover, industrial dalfopristin procurement is influenced by factors including the cost and availability of specialised raw materials, strict regulatory compliance for injectable antibiotics, and adherence to environmental and quality standards. Furthermore, advancements in production technologies, reliable supplier capabilities, sustainable production practices, and efficient logistics systems strongly impact its procurement processes at the global level.

Raw Material for Dalfopristin Production

According to the dalfopristin production plant project report, the major raw materials for dalfopristin production include Streptomyces bacteria.

Production Process of Dalfopristin

The extensive dalfopristin production cost report consists of the following industrial production process:

1. Production via Fermentation: The production process of dalfopristin begins with the fermentation of Streptomyces bacteria to produce pristinamycin IIA, which is then extracted and purified on a large scale. In the main chemical step, 2-diethylaminoethanethiol is added via a stereoselective Michael addition to the dehydroproline ring under controlled reaction conditions. The intermediate thioether is oxidised to the sulfone using hydrogen peroxide and a catalyst like sodium tungstate in a two-phase solvent system for high yield and purity. Finally, crystallisation, followed by drying, milling, and formulation into the final injectable product under sterile GMP conditions, results in the formation of dalfopristin as the desired product.

Dalfopristin is a semi-synthetic streptogramin antibiotic derived from pristinamycin IIA, and it acts by inhibiting the early phase of bacterial protein synthesis. It appears as a slightly yellow to yellow hygroscopic powder. The molecular formula of the compound is C34H50N4O9S, and its molar mass is 690.85 g/mol. The mesylate salt of the compound exhibits high water solubility (>100 mg/mL) and is also soluble in ethanol, methanol, and dimethyl sulfoxide. It has a density of around 1.27 gm/cm3. Common adverse effects associated with dalfopristin-containing therapy include infusion-site reactions such as phlebitis, musculoskeletal symptoms including myalgias and arthralgias, and potential for Clostridium difficile-associated diarrhoea. The melting point of the compound is approximately 150 degree Celsius, and its boiling point is around 940.5 degree Celsius.